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Abstract
Background
Levothyroxine (LT4) and rifampin (RIF) are sometimes used together; however, no clinical
studies have assessed the effects of these drugs on thyroid function or the need to adjust
LT4 dose.
Methods
We retrospectively reviewed the records of 71 Korean patients who started RIF during LT4
treatment. Clinically relevant cases that required dose adjustment according to the Ameri-
can Thyroid Association (ATA)/American Association of Clinical Endocrinologists (AACE)
guidelines were identified, and risk factors of increased LT4 dose were analyzed.
Results
After administering RIF, median serum thyroid-stimulating hormone (TSH) level (2.58 mIU/
L, interquartile range [IQR] 0.21–7.44) was significantly higher than that before RIF (0.25
mIU/L, IQR, 0.03–2.62; P < 0.001). An increased LT4 dose was required for 50% of patients
in the TSH suppression group for thyroid cancer and 26% of patients in the replacement
group for hypothyroidism. Risk factor analysis showed that remaining thyroid gland (odds
ratio [OR] 9.207, P = 0.002), the time interval between starting RIF and TSH measurement
(OR 1.043, P = 0.019), and baseline LT4 dose per kg body weight (OR 0.364, P = 0.011)
were clinically relevant variables.
Conclusions
In patients receiving LT4, serum thyroid function test should be performed after starting RIF
treatment. For patients with no remnant thyroid gland and those receiving a lower LT4 dose,
close observation is needed when starting RIF and TB medication.
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Introduction
Levothyroxine (LT4) is widely used to replace thyroid hormone in patients with hypothyroid-
ism and to suppress serum thyroid-stimulating hormone (TSH) for the treatment of differenti-
ated thyroid cancer (DTC). The primary pathway of LT4 metabolism is sequential
deiodination. The main site of deiodination is the liver, although several other organs includ-
ing the kidneys also metabolize LT4. LT4 is a substrate for CYP3A4, a member of the hepatic
cytochrome P450 family of enzymes. Approximately 80% of LT4 is eliminated by the kidneys,
and the remaining 20% is eliminated in the stool [1].
Rifampin (RIF) is used to treat active tuberculosis (TB) and latent TB infection (LTBI), as
well as disease caused by nontuberculous mycobacteria (NTM) such as Mycobacterium avium
complex. These mycobacterial diseases require long-term RIF treatment. RIF is a potent
inducer of hepatic cytochrome P450 enzymes, especially CYP3A4, thus increasing the metabo-
lism of many drugs that are metabolized by the liver [2,3].
In some patients undergoing LT4 treatment, elevated TSH leads to an increase in LT4 dose
after administration of RIF. The American Thyroid Association (ATA)/American Association
of Clinical Endocrinologists (AACE) hypothyroidism guidelines recommend measuring TSH
within 4–8 weeks after starting a drug that might influence LT4 dose, such as RIF [4]. How-
ever, only a few case reports have noted LT4 and RIF drug interactions leading to elevated
TSH [5–7]. Furthermore, no retrospective or prospective clinical studies in the English lan-
guage literature have evaluated elevated TSH level after administering RIF in patients receiving
LT4.
In this study, we investigated the effect of RIF on thyroid function in patients undergoing
LT4 therapy. We also analyzed risk factors of a clinically relevant change in thyroid function.
Materials and Methods
Study population
This study was a retrospective cohort study of adults who started RIF treatment during LT4
treatment between November 1994 and June 2014 at Samsung Medical Center (a 1,961-bed
referral hospital in Seoul, South Korea). Patients 18 years or younger and those who took RIF
for diseases other than TB, LTBI, or NTM infection were not included. We also excluded
patients administered RIF for less than 4 weeks and patients with an obvious cause for a
change in thyroid function, including LT4 discontinuation due to poor compliance or in prep-
aration for radioiodine treatment. Seventy-one Korean patients were enrolled in this study.
The study population was divided into two groups based on the reason for LT4 treatment: LT4
replacement to manage hypothyroidism and TSH suppression to manage DTC.
Study design and outcome measurement
The primary outcome of this study was change in thyroid function as measured by serum TSH
and free thyroxine (fT4) after RIF administration. The secondary outcome was the percentage
of patients with a clinically relevant change in thyroid function leading to a need for LT4 dose
adjustment. A clinically relevant change in thyroid function was defined as a change that
required LT4 dose adjustment according to the ATA/AACE guidelines. In the LT4 replace-
ment group, a serum TSH level that exceeded the upper normal limit after starting RIF was
classified as clinically relevant by 2012 ATA/AACE hypothyroidism guidelines [4]. For the
suppression group, a clinically relevant change was defined as a serum TSH increase above the
target TSH range according to the revised 2015 ATA guidelines for DTC after RIF administra-
tion [8,9].
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The following factors were investigated for possible biological and/or pharmacological asso-
ciations with LT4 dose adjustment: age, sex, reason for LT4 treatment, LT4 dose, reason for
RIF treatment, RIF dose, time interval between starting RIF and serum TSH measurement,
underlying liver disease, and underlying renal disease [10,11].
Statistical analysis
All variables including baseline characteristics are presented as number with percentage for
categorical variables, mean ± standard deviation (SD) for continuous variables following a
normal distribution, and median with interquartile range (IQR) for continuous variables not
following a normal distribution. Changes in serum TSH and serum free T4 were evaluated
using the Wilcoxon signed rank test (Wilcoxon matched pairs test). Bivariate analysis of vari-
ables between clinically relevant and clinically irrelevant changes in thyroid function were per-
formed with the Student’s t-test for continuous variables following a normal distribution,
Mann-Whitney U test for continuous variables not following a normal distribution, Chi-
square test for categorical variables, and Fisher’s exact test for categorical variables with an
expected frequency less than five. Age, sex, liver disease, renal disease, RIF-TSH duration, rem-
nant thyroid, etiology of RIF, RIF dose, and LT4 dose were used as covariates of multivariable
analysis. Binary logistic regression with likelihood ratio test and backward elimination was
used for multivariable analysis. All statistical analyses were performed with SPSS Statistical
Software package version 22.
Ethics
The data used in this study were made available in an anonymized format, and the need for
informed consent was waived. This retrospective observational study was approved by the
Institutional Review Board of Samsung Medical Center (IRB No. 2015-08-101), and full per-
mission was granted to review and publish information obtained from patient records.
Results
The study population (N = 71) was divided into a TSH suppression group who received LT4 to
suppress DTC recurrence (N = 46) and a TSH replacement group who took LT4 to replace
thyroid hormone (N = 25). Baseline characteristics of the study population are presented in
Table 1. Most patients were female (N = 58, 82%) and the median age was 52 years (IQR, 46–
60 years). Median LT4 dose was 2.00 μg/kg/day (IQR, 1.49–2.54). The suppression group had
a higher LT4 dose than did the replacement group. The most common reason to administer
RIF was TB (N = 49, 69%). The median time between the start of RIF and serum TSH mea-
surement was 32 weeks (IQR, 20–42 weeks). Baseline serum TSH level before administering
RIF was 0.25 mIU/L (median, IQR, 0.03–2.62 mIU/L), and baseline serum fT4 level was 1.34
ng/dL (median, IQR, 1.12–1.61 ng/dL). Some patients had underlying liver disease (N = 11,
15%) or kidney disease (N = 5, 7%).
Table 2 shows serum TSH and fT4 levels before and after administering RIF. Median serum
TSH levels before and after administering RIF were 0.25 mIU/L (IQR, 0.03–2.62 mIU/L) and
2.58 mIU/L (IQR, 0.21–7.44 mIU/L), respectively. Serum TSH levels after administering RIF
were significantly higher than those before administering RIF (P< 0.001). Conversely, median
serum fT4 levels decreased significantly after RIF was administered (1.34 ng/dL [IQR 1.12–
1.61] to 1.01 [0.90–1.28], P< 0.001). Fifty percent of patients in the TSH-suppression group
(23/46) and 24% in the simple replacement group (6/25) experienced changes in TSH that
required an increase in LT4 dose according to ATA/AACE guidelines.
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When patients with clinically relevant and irrelevant changes were compared, remnant thy-
roid (P = 0.002, Chi-square test), reason for LT4 treatment (P = 0.04, Chi-square test), and
time between starting RIF and TSH measurement (P = 0.005, Mann-Whitney U test) were sig-
nificantly different (Table 3). Other variables such as age, sex, LT4 dose, reason for administer-
ing RIF, RIF dose, underlying liver disease, and underlying renal disease did not differ
significantly between groups. In multivariate analysis, lack of remnant thyroid (hazard ratio
[OR] 9.20, 95% confidence interval [CI] 2.28–37.17, P = 0.002), time between starting RIF and
serum TSH measurement (OR 1.04, 95% CI 1.00–1.08, P = 0.019), and LT4 dose per kg body
weight (OR 0.36, 95% CI 0.16–0.79, P = 0.011) were clinically significant (Table 4, Model 2).
More detailed statistical values for each statistics in Tables 2–4 could be found in S1 Table. For
every one-week increase in the time between the start of RIF and TSH measurement, the odds
of an LT4 dose increased 1.04 times. However, the odds were no longer clinically significant
beyond 40 weeks after the start of RIF when logistic regression was performed stepwise accord-
ing to time interval.
Table 1. Baseline characteristics of enrolled patients taking levothyroxine before starting rifampin.
TSH suppression group (n = 46) LT4 replacement group (n = 25) Total (n = 71)
Age, median (IQR) 49 (43–59) 57 (50–66) 52 (46–60)
Female, n (%) 40 (87) 18 (72) 58 (82)
Body weight, kg, median (IQR) 56 (51–61) 55 (51–66) 56 (51–62)
LT4 dose, μg/kg/day, median (IQR) 2.15 (1.83–3.13) 1.47 (0.98–2.34) 2.00 (1.49–2.54)
Reason for RIF administration
TB, n (%) 28 (60) 18 (72) 49 (69)
LTBI, n (%) 3 (6) 2 (8) 5 (7)
NTM, n (%) 15 (32) 5 (20) 17 (23)
RIF dose, mg/kg/week, median (IQR) 70 (55–77) 64 (54–73) 69 (54–76)
Time after starting RIF, weeks, median (IQR) 37 (22–43) 25 (15–38) 32 (20–42)
Baseline TSH level, mIU/L, median (IQR) 0.16 (0.01–1.39) 2.30 (0.19–9.85) 0.25 (0.03–2.62)
Baseline fT4 level*, ng/dL, median (IQR) 1.53 (1.29–1.65) 1.20 (0.88–1.29) 1.34 (1.12–1.61)
Underlying liver disease, n (%) 2 (4) 9 (36) 11 (15)
Underlying kidney disease, n (%) 3 (6) 2 (8) 5 (7)
*For 27 patients and 17 patients in the TSH suppression and LT4 replacement groups, respectively.
All categorical variables are expressed as a percentage (%) and all continuous values are expressed as the median and interquartile range (IQR) because
none of the variables follow a standard distribution.
TSH, thyroid-stimulating hormone; LT4, levothyroxine; RIF, rifampin; TB, active tuberculosis; LTBI, latent TB infection; NTM, nontuberculous mycobacteria
disease; fT4, free thyroxine.
doi:10.1371/journal.pone.0169775.t001
Table 2. Thyroid profile before and after RIF administration.
Before RIF After RIF P-value
TSH, mIU/L, median(IQR) 0.25 (0.03–2.62) 2.58 (0.21–7.44) P < 0.001a
fT4, ng/dL, median(IQR) 1.34 (1.12–1.61) 1.01 (0.90–1.28) P < 0.001a
aWilcoxon signed rank test (Wilcoxon matched pairs test)
Abbreviations: TSH, thyroid-stimulating hormone; RIF, rifampin; fT4, free thyroxine
doi:10.1371/journal.pone.0169775.t002
Effect of RIF on Thyroid Function Test in Patients on LT4 Medication
PLOS ONE | DOI:10.1371/journal.pone.0169775 January 12, 2017 4 / 8
Discussion
In this retrospective analysis, we investigated the effects of RIF on the thyroid function of
patients who were taking LT4. Our data showed that serum TSH level significantly increased
and serum fT4 level significantly decreased after starting RIF treatment. Furthermore, 50% of
patients in the TSH-suppression group and 26% of patients in the replacement group required
an LT4 dose increase to maintain target serum TSH according to the ATA/AACE guidelines.
Our results support recommendation 16 of the ATA/AACE hypothyroidism guidelines, which
recommends measuring TSH within 4–8 weeks after starting a drug, such as RIF, that might
influence LT4 dose [4].
Table 3. Risk factor analysis (bivariate) of clinically relevant changes in TSH.
Variables Clinically non-relevant (n = 42) Clinically relevant (n = 29) P-value
Age, median (IQR) 54 (45–60) 49 (46–65) 0.497 b
Male, n (%) 8 (19) 5 (17) 0.847 a
Reason for LT4, n (%) PTC 23 (54) 23 (79) 0.04 a
Others 19 (45) 6 (20)
Reason for RIF, n (%) TB 31 (73) 18 (62) 0.503 a
LTBI 2 (4) 3 (10)
NTM 9 (21) 8 (27)
Remnant thyroid, n (%) 30 (71) 10 (34) 0.002 a
LT4 dose, μg/kg/day, mean ± SD 2.20 ± 1.12 2.04 ± 0.63 0.434 b
RIF dose, mg/kg/week, median (IQR) 69 (55–74) 70 (45–77) 0.874 b
Time after starting RIF, weeks, median (IQR) 26 (15–38) 41 (23–57) 0.005 b
Baseline TSH level, mIU/L, Median (IQR) 0.21 (0.10–4.62) 0.29 (0.08–2.40) 0.906 b
Baseline fT4 level, ng/dL, mean ± SD 1.30 ± 0.09 1.42 ± 0.06 0.349 b
Underlying liver disease, n (%) 8 (19) 6 (20) 0.864 a
Underlying kidney disease, n (%) 3 (7) 2 (6) 1.000 a
aChi-square test
bMann-Whitney U test
TSH, thyroid-stimulating hormone; LT4, levothyroxine; RIF, rifampin; TB, active tuberculosis; LTBI, latent TB infection; NTM, nontuberculous mycobacteria
disease; fT4, free thyroxine; PTC, papillary thyroid cancer
doi:10.1371/journal.pone.0169775.t003
Table 4. Risk factor analysis (multivariate) of clinically relevant cases.
Variable OR (95% CI) P-value
Model 1 No remnant thyroid 3.52 (1.21–10.26) 0.021 a
Time after starting RIF 1.03 (1.00–1.06) 0.034 a
Model 2 No remnant thyroid 9.20 (2.28–37.17) 0.002a
Time after starting RIF 1.04 (1.00–1.08) 0.019a
LT4 dose 0.36 (0.16–0.79) 0.011a
aBinary logistic regression analysis with backward LRT
Model 1: age, sex, RIF-TSH duration, remnant thyroid
Model 2: Model 1 + liver disease, renal disease, etiology of RIF, RIF dose, LT4 dose
‘Reason for LT4 treatment’ was not included in the logistic regression model because of multi-collinearity
with ‘remnant thyroid.’
TSH, thyroid-stimulating hormone; LT4, levothyroxine; RIF, rifampin
doi:10.1371/journal.pone.0169775.t004
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In contrast, Christensen et al. reported no significant change in serum TSH or fT4 in 13
healthy volunteers who took RIF for 28 days [12]. In their study, thyroid volume and antipy-
rine clearance increased significantly, but there were no significant changes in serum TSH and
fT4 levels. This result implies that RIF increased T4 clearance in the liver, but did not change
serum TSH or fT4 due to compensation by the normal thyroid gland. This discrepancy likely
reflects differences in study populations. Patients who take LT4 in normal clinical practice usu-
ally have little or no remaining thyroid function to compensate for increases in LT4 clearance.
In fact, a lack of remaining thyroid and lower LT4 dose upon starting RIF were risk factors of
clinically relevant changes in thyroid function in our study.
LT4 dose per kg body weight at the time of RIF administration was a significant risk factor
in multivariate analysis, but not in bivariate analysis. This result could be explained by the con-
founding effect of remaining thyroid gland. The clinically irrelevant group contained more
patients with remaining thyroid who were taking lower doses of LT4 and patients who were
already taking a relatively high dose of LT4 before starting RIF compared with the clinically
relevant group. Use of the mean LT4 dose in bivariate analysis might have masked any differ-
ences in LT4 dose. However, when we adjusted for remaining thyroid (see methods), LT4 dose
per kg body weight became a significant risk factor.
The time between starting RIF and measuring serum TSH was a risk factor of LT4 dose
adjustment in both bivariate and multivariate analyses; however, this effect disappeared 40
weeks after starting RIF. RIF induces CYP3A4 in approximately 3 days. However, when
another drug (i.e., a CYP3A4 substrate) is added, the new equilibrium depends on the second
drug, an effect known as drug-drug interaction (DDI). For example, a combination of steroid
and RIF requires 2 weeks to reach a new equilibrium. Dynamic DDI modeling with RIF
revealed that the new equilibrium time is proportional to the half-life of the substrate [10,13].
The half-life of prednisolone is 12–36 hours and reaches a new equilibrium with RIF in about
2 weeks. The exact equilibrium time of RIF and LT4 has not been determined, but more than
4–8 weeks might be required to reach a new equilibrium because the half-life of LT4 (approxi-
mately 190 hours) is much longer than that of prednisolone. Our data suggest that TSH level
should be checked periodically at 4–8 weeks as recommended by 2012 ATA/AACE hypothy-
roidism guidelines, but also at about 40 weeks.
Past studies have documented that isoniazide (INH) is the substrate of N-acetyltransferase.
The slow-acetylator phenotype (poor metabolizers) is prone to INH side effects due to
increased blood INH concentration. INH inhibits CYP3A, contrary to RIF, and thus RIF
might have a weaker effect on CYP3A in slow acetylators. In this study, most patients took
INH and RIF together, but all patients were Korean and only 10–15% of Koreans are expected
to be slow acetylators [14–16]. In contrast, in Caucasians and African Americans, the preva-
lence of slow acetylators is approximately 50% [17–19]. Considering that the prevalence of
slow acetylators is only 10–15% in Koreans while there are 50% in Caucasians and African
Americans, the effect of RIF with con-concomitant INH on LT4 clearance might have been
more prominent in this study population than other ethnicities.
The small study population from a single tertiary referral center is a limitation of this study,
and a further study in a larger population is warranted. In addition, quality of life (for example,
symptoms of hypothyroidism such as general weakness or weight gain) was not investigated
because of the weakness of the retrospective design.
In conclusion, serum TSH increased and fT4 decreased significantly after the start of RIF
treatment in patients taking LT4 for either hormone replacement for hypothyroidism or TSH
suppression to manage DTC. Therefore, clinicians should closely monitor thyroid function
when RIF is administered, particularly in patients without remaining thyroid gland and those
taking a low dose of LT4. Further studies are needed to confirm these results, especially in
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populations where slow acetylators are more prevalent, such as in Caucasians and African
Americans.
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